Mesenchymal stem cells (MSC) have recently been used successfully in humans to control severe graft-versus-host disease. However, the mechanisms involved in their immunomodulatory effects remain a matter of debate. Here, we show that MSC are unable to activate allogeneic T cells even in the presence of T-cell growth factors. We then found that MSC inhibit T-cell proliferation triggered either by allogeneic, mitogenic or antigen-specific stimuli. Interestingly, MSC inhibit T-cell proliferation by inducing apoptosis of activated T cells, but have no effect on resting T cells. Furthermore, we show that this apoptosis could be related to the conversion of tryptophan into kynurenine by indoleamine 2,3-dioxygenase expressed by MSC in the presence of IFNc. Moreover, we show that the inhibitory effect of MSC is neither abrogated nor modified during expansion in culture or after irradiation. Together, these results bring new insight to the mechanisms of immunosuppression induced by MSC and might help to develop their clinical use controlling immune-related adverse effects in humans.
Introduction
Adult mesenchymal stem cells (MSC) or bone marrow (BM) stromal cells have the capacity of self-renewal. 1, 2 In human BM, they represent only 0.001% of the nucleated cells. 3 As a result of the optimization of the human MSC culture process and their multilineage potential, they have been extensively studied as a potential tool in cell and gene therapy for tissue repair or hematopoiesis support. Allogeneic or autologous MSC have already been used clinically to improve hematopoietic recovery after autologous stem cell transplantation in advanced breast cancer patients 4 or to treat children with osteogenesis imperfecta. 5, 6 Recently, MSC were used clinically for their immunomodulatory potential. 7 Haploidentical MSC were transplanted in a 9-year-old boy suffering from treatment-resistant, severe, acute graft-versus-host disease (GVHD). Two injections of MSC led to an immunosuppressive effect, resulting in clinical response. In an animal model, 8 the immunomodulation potential of MSC was found to prolong skin graft survival. In vitro, MSC were shown to be poorly immunogenic and to suppress allogeneic or autologous T-cell responses. [9] [10] [11] [12] [13] However, the mechanisms involved in the immunological properties of MSC remain a matter of debate. Here, we specify those immunological properties and show that MSC inhibit T-cell proliferation through the induction of activated T-cell apoptosis. The expression of indoleamine 2,3-dioxygenase (IDO) by MSC might be responsible for the apoptosis induced. Moreover, because therapeutic MSC are expanded ex vivo, we analyzed the modifications of their immunological functions induced by cell culture.
Materials and methods

Cells
Human MSC and peripheral blood mononuclear cells (PBMC) were, respectively, isolated from BM aspirates and cytapheresis from healthy donors who gave informed consent. Mononuclear cells were obtained by Ficoll-Hypaque density gradient centrifugation. MSC were selected by adherence and cultured in flasks in alpha-MEM medium (Sigma, l'Isle d'Abeau, France) supplemented with 10% of heat-inactivated fetal calf serum (FCS) (Life Technologies, Grand Island, NY, USA) as previously described.
14 MSC were recovered from passages 1-4 following trypsin-0.01% EDTA treatment. The MSC retained the capacity to differentiate into adipogenic, osteogenic and chondrogenic lineages (data not shown). In some cultures, basic fibroblast growth factor (bFGF, BD Biosciences, Palo Alto, USA) was added to the medium (1 ng/ml). Cells were cryopreserved until assays were carried out. HLA typing of cells is shown in Table 1 .
Reagents
The following antibodies were used unconjugated or conjugated with fluorescein isothiocyanate or phycoerythrin: CD3, CD11a, CD14, CD19, CD40, CD45, CD54, CD58, CD80, CD86, HLA-I and HLA-II, purchased from Immunotech (Marseille, France); CD73 and CD90 from Pharmingen (San Diego, USA); CD105 from Ancell (Bayport, USA). MHC tetramer (HLA-A n 0201/ MP58-66 (GILGFVFTL)) was purchased from Immunomics (Fullerton, USA). Cytokine detection (IFNg) was performed using a Cytometric Bead Array (CBA) kit (Pharmingen, San Diego, USA).
Cell cultures
Cell cultures were performed in complete medium (RPMI 1640 containing 1 mM sodium pyruvate, 2 mM L-glutamine, 20 mg/ml gentamycin and nonessential amino acids) supplemented with 10% fetal calf serum, in quadruplicate, in 0.2 ml in 96-well flatbottom plates. Unidirectional mixed leukocyte culture (MLC) were performed by mixing 7.5 Â 10 4 responding PBMC and 7.5 Â 10 4 irradiated ( n , 30 Gy) stimulator PBMC. After a 5-day incubation at 371C in 5% CO 2 in humidified air, 1 mCi [ 3 H]thymidine was added to each culture and cells were harvested 18 h later. Results are expressed in c.p.m. as the mean value of quadruplicates. In some experiments, IL-2 (Roussel-Uclaf, Romainville, France) and IFNg (Peprotech, Rocky Hill, USA) were added at 20 IU/ml and 100 ng/ml, respectively. For inhibition experiments, azide-free blocking antibodies: anti-HGF (24612.11), anti-TGF-b1 (141322), anti-IL-6 (6708.111) from R&D systems (UK), anti-TRAIL (2E5, Alexis Biochemicals, USA), anti-Fas (ZB-4, Immunotech) and IgG1 isotype controls were added, at the indicated concentrations, to the culture medium at the beginning of the culture. In some cases, PBMC (1 Â 10 5 ) were activated for 3 days with PHA (2 mg/ ml, Murex), ConA (20 mg/ml, Sigma) or CD3 (10 ng/ml, Diaclone, France). For the generation of antigen-specific CD8 þ T cells, HLA-A2( þ ) dendritic cells, generated from monocytes in the presence of GM-CSF and IL-4 for 6 days, were infected with influenza virus (Aventis Pasteur, Val de Reuil, France) and cultured for 7 days with purified autologous CD8 T cells (T/DC ratio ¼ 10/1).
Except as mentioned, 5 Â 10 4 irradiated (30 Gy) MSC were added to each well of the culture plate (PBMC activated or not, MLC and antigen-specific T cells). For large number of cells, cultures were performed in 24-well plates and the same cell ratio and concentration were used.
Conditioned media
MSC-conditioned medium was produced by culturing MSC in 75-cm 2 flasks at 70-90% confluence. Supernatants from two cultures from passages 1 to 3 were pooled, aliquoted and cryopreserved until use. Conditioned media (CM) from MLC culture in the presence or absence of MSC were recovered at the end of a 6-day culture and cryopreserved until use. Conditioned media were added at the beginning of the cultures as mentioned.
Cell viability
Cell viability was evaluated by staining with 2.5 mg/ml propidium iodide (PI, Immunotech) and flow cytometer analysis. Annexin V (Immunotech) and DiOC 6(3) (Molecular Probes) staining were used to confirm the apoptotic process as shown elsewhere. 15 
Western blot analysis
As previously described, 16 PBMC were washed in PBS, lysed in sample buffer (Sigma) and heated at 1001C for 5 min. The whole extract of 1 Â 10 6 cells was loaded onto a 12% SDSpolyacrylamide gel and, after electrophoresis, proteins were transferred to a PVDF membrane (BIORAD, Marne la Coquette, France). After blocking nonspecific binding sites with 5% nonfat milk in PBS-0.1% Tween 20, the membranes were incubated with primary antibodies: anti-procaspase-2 (Santa Cruz Biotechnology, Santa Cruz, USA), anti-procaspase-9 (Immunotech), anti-caspase-3, anti-PARP (Pharmingen) and anti-actin (Sigma). Antibody labelling was revealed using goat anti-rabbit or antimouse horseradish peroxidase (HRP) conjugated secondary antibodies (Immunotech) and was visualized using enhanced chemiluminescence (ECL) (Amersham Life Science, Les Ulis, France).
Detection of IDO activity
IDO expression was detected by intracellular staining. JEG3 cells or MSC not treated or treated with IFNg for 3 days were centrifuged on glass slides, permeabilized by acetone fixation, and cryopreserved. After thawing and rehydration, the incubation with primary antibodies: anti-HLA-I (W6/32, Serotec, Oxford, UK) or anti-IDO (Chemicon, Hampshire, UK) was followed by incubation with fluorescein isothiocyanate (FITC)-goat anti-mouse immunoglobulin and counterstaining with Evan's blue dye (Sigma, Saint Quentin Fallavier, France). JEG3 is a human trophoblast-derived cell line kindly provided by P Le Bouteiller (INSERM U395, Toulouse, France). 17 IDO activity was determined by measuring the tryptophan into kynurenine conversion in the culture supernatant. Tryptophan and kynurenine concentrations were determined by high-performance liquid chromatography (HPLC).
Results
MSC do not activate allogeneic T cells even in the presence of T-cell growth factors
Cultured MSC used in this study are characterized by their phenotype as shown in Figure 1a . As expected, MSC expressed CD73, CD90 and CD105 but were CD45 À Lin À (CD3, CD19, CD56, CD14). HLA-I expression was positive. HLA-DR, CD40, CD80 and CD86, molecules related to antigen-presenting cells, were negative, suggesting an inability of cultured MSC to induce T-cell activation. However the expression of CD54 and CD58 could allow cooperation with T cells via CD11a/CD18 (LFA-1) and CD2 molecules constitutively expressed on T cells. Functionally, MSC were unable to induce any proliferation of allogeneic T cells (Figure 1b ). IL-2 and IFNg are two cytokines involved in activation and expansion of both CD4 and CD8 T cells. Moreover, IFNg has been shown to induce HLA class II expression on MSC, 12 and IL-2 is necessary for the growth of CD8 in culture without CD4 T cells. Results presented in Figure 1b show that addition of these cytokines did not enable T-cell proliferation when MSC were present in the culture. Interestingly, background proliferation of T cells in the presence of IL-2 was inhibited by MSC ( Figure 1b) .
bFGF is often added in culture to improve MSC amplification. We wondered whether bFGF could modify the allostimulatory capacities of MSC. We found that culturing with bFGF induced expression of HLA-II and CD40 molecules (Figure 1c ), without upregulating CD80 and CD86 (not shown). Despite the expression of these molecules, MSC cultured with bFGF did not induce T-cell proliferation (Figure 1d ).
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We next focused on the capacities of MSC to inhibit proliferation of T cells triggered either by allogeneic, mitogenic or antigen-specific stimuli. We chose the one-way allogeneic MLC model to study the proliferation of both allogeneic CD4 and CD8 T cells. We set up a full allogeneic assay by adding to MLC, MSC from an allogeneic third party (see HLA types in Table 1 ). Figure 2a shows that inhibition of T-cell proliferation is dependent on the amount of MSC in the culture. With a large amount of MSC (5 Â 10 4 ), the proliferation of T cells (7.5 Â 10 4 ) from PBMC was completely inhibited. Interestingly, the inhibitory effect was observed with or without g-irradiation of MSC , suggesting that the inhibitory mechanism is radioresistant ( Figure 2b ). Since MSC are usually obtained following successive passages, we wondered whether this could influence their capacities to interfere with T-cell proliferation. As shown in Figure 2c , the MSC phenotype did not change from passage 1-4: similar levels of CD73, CD90 and HLA-I expression were found, and HLA-II, CD40 and CD80 remained negative. Functionally, MSC obtained at 1-4 passages displayed the same inhibitory effect in MLC (Figure 2d) .
We next tried to restore the proliferation of T cells by adding T-cell growth factors. As shown in Figure 3a , neither the addition of IL-2 nor the addition of IFNg overcame the inhibitory effect of MSC. In addition, MSC were also able to inhibit T-cell proliferation induced by mitogenic stimuli such as PHA, ConA or CD3 (Figure 3b ). Once again, the addition of IL-2 to these cultures did not restore T-cell proliferation. To determine whether the inhibitory effect of MSC could target only a fraction of the antigen-specific T-cell population, we developed an antigen-specific assay using the influenza virus model. HLA-A2 þ dendritic cells were infected with influenza virus and then cocultured with autologous CD8 T cells for 6 days in the presence or absence of MSC. At the beginning and the end of the culture, the frequency of anti-virus CD8 T cells was monitored by the binding of MHC tetramer (HLA-A2/MP58-66). In the absence of MSC, the initial frequency of specific T cells (1.8%) increased after 6 days (28.2%), revealing a strong expansion of specific CD8 T cells (Figure 3c ). Interestingly, when MSC were present in culture, only a slight growth of anti-viral T cells was observed (2.6%). 
MSC induce cell death in activated T cells
Previous data in this work and in the literature use inhibition of the proliferation of T cells to demonstrate the inhibitory effects of MSC. Here, we decided to compare the number of cells at the beginning and at the end of cultures in MLC assays. We performed two MLC in the presence or absence of third-party MSC. As expected, with MSC, a 90% inhibition of proliferation was observed (not shown) and, surprisingly, the number of cells at the end of the culture was dramatically reduced (Figure 4a) . At the beginning of the MLC, about 6 Â 10 6 viable responder and irradiated stimulator PBL were mixed in the presence or absence of 4 Â 10 6 MSC. At the end of the 6-day culture without MSC, the number of cells increased due to the proliferation of T cells (up to 10 Â 10 6 ). In contrast, in culture with MSC, the number of recovered cells was below 1.8 Â 10
6 , suggesting cell death. We hypothesized that MSC triggered activationinduced cell death. In order to confirm the requirement of T-cell activation in the sensitivity to death mediated by MSC, we cocultured PBL without stimulation in the presence or absence of MSC and determined the cell viability. As shown in Figure 4b , the percentage of viable PBL under resting conditions was not modified by the presence of MSC during the 3-day coculture. Since the use of irradiated stimulator cells could interfere with the evaluation of cell viability, we decided to activate T cells directly via their T-cell receptor by using CD3 mitogenic activation. Interestingly, we found that, compared to T cells cultured in medium alone, the presence of MSC led to a dramatic decrease in activated T-cell viability (70 vs 35%) after only one day of culture (Figure 4c ). These results clearly indicate that MSC trigger early death of activated T cells. By using Annexin-V and DioC6 labelling, we confirmed that activated T cells died through an apoptotic mechanism in the presence of MSC (Figure 5a ). MSC-induced apoptosis was also evidenced by the cleavage of pro-caspase-2, pro-caspase-9, pro-caspase-3 and the caspase-3 substrate PARP (Figure 5b ). The cleavage of pro-caspase-2 and pro-caspase-9 suggests that the mitochondrion was involved in the apoptotic process.
MSC express functional IDO
Several hypotheses have been put forward to explain the immunosuppressive activity of MSC. Apoptosis could be induced by death receptors such as CD95 (Fas) or TRAIL (TNF-related apoptotic inducing ligand) receptors, but MSC did not express CD95-ligand or TRAIL (data not shown). Moreover, the addition of blocking antibodies against CD95 (ZB4 clone) or TRAIL (2E5 clone) in CD3-mitogenic assays did not affect the inhibitory effect of MSC (data not shown), indicating that apoptosis was not mediated by these death receptors.
Since the inhibitory activity on T-cell proliferation was huge in MLC, mitogenic and antigen-specific assays, we hypothesized that MSC could secrete inhibitory or death-inducing factors. We first analyzed the effects of conditioned medium (CM) from MSC cultures on T-cell proliferation in MLC. A partial inhibition was observed when 50% of the culture medium was replaced by CM (Figure 6a ). We then tried to evaluate the involvement of some potential suppressor factors such as hepatocyte growth factor (HGF) and transforming growth factor-beta (TGF-b) as described in other studies. 9, 13 Since MSC produced large amounts of IL-6 (not shown), we also included blocking antibody against IL-6 in this assay. As shown in Figure 6b , none of these factors seemed to be responsible for inhibition of T-cell proliferation. Finally, we wondered whether a potential inhibitory factor could be synthesized by MSC in the presence of T cells or be dependent on the activation of T cells in the MLC assay. We tested CM from initial MLC culture in the presence or absence of MSC, on the proliferation of T cells in an independent MLC (Figure 6c) . Only a slight inhibition was found, suggesting that the inhibitory mechanism of MSC is marginally mediated through the secretion of soluble factors.
We then tested the possible involvement of IDO, an enzyme that catalyzes the conversion of tryptophan into kynurenine, leading to T-cell apoptosis. 18 Firstly, we evaluated the expression of IDO by intracellular staining. In Figure 7a , we used a trophoblast-derived cell line JEG-3 as positive control and we analyzed both the HLA class I molecule and the IDO protein.
As expected, JEG-3 showed positive labelling in both cases. In resting MSC, we detected HLA class I molecules, but IDO expression was found to be negative. However, when MSC were cultured with IFNg for 3 days, the level of HLA class I expression increased and they strongly expressed IDO. We then measured the level of tryptophan and kynurenine concentrations in MSC supernatant and in MLC in the presence or absence of MSC. The measurement of the conversion of tryptophan into kynurenine reflects the IDO activity. In the culture of MSC without IFNg, the concentration of tryptophan was high (25 mM) and that of kynurenine was very low (0.5 mM, data not shown), suggesting an absence of IDO activity. Interestingly, IDO activity was detected in MLC performed in the presence of MSC. As shown in Figure 7b , there was no conversion of tryptophan into kynurenine in MLC without MSC, as evidenced by the presence of tryptophan (about 11 mM) and the absence of kynurenine. By contrast, in MLC in the presence of MSC, no tryptophan could be detected, while the levels of kynurenine were high (10 mM). These results strongly suggest that soluble factors secreted during MLC could induce IDO activity in MSC, leading to the conversion of tryptophan into kynurenine.
Discussion
MSC are attractive and promising tools in human medicine because of their involvement in tissue repair, hematopoietic support or modulation of the immune response. In the latter indication, MSC have been shown to have peculiar immunological features. They are poorly immunogenic and suppress allogeneic or autologous T-cell responses. [9] [10] [11] [12] [13] In the baboon model, MSC injection enabled skin graft survival to be prolonged. 8 These results have encouraged their clinical use for the treatment of severe acute GVHD. 7 However, the mechanisms of this immunuosuppression are not clearly understood. Here, we show that MSC induce early apoptosis of activated T cells.
The induction of apoptosis by MSC could account for their broad immunosuppression of T-cell proliferation that is observed with all tested stimuli. Indeed, we show a 90% inhibition of proliferation in allogeneic and in mitogenic assays. Moreover, antigen-specific response was also reduced in the presence of MSC, as quantified by the frequency of specific T cells. The apoptosis was clearly restricted to activated T cells. The addition of cytokines such as IL-2 or IFNg, known to prevent activationinduced cell death, did not rescue activated T cells from apoptosis, but rather induced apoptosis of responding T cells.
Apoptosis could be induced by several mechanisms. CD95 or TRAIL death receptors are not involved because MSC are negative for their respective ligands, and addition of blocking antibodies to cocultures did not restore the proliferation of T cells. Several reports have explored whether inhibition of T-cell activation by MSC could be mediated by soluble factors, but the results are not concordant. [9] [10] [11] 13 In this study, we did not find that MSC secrete soluble inhibitory factors as suggested by Krampera et al. 10 Conditioned medium from MSC culture or from MLC in the presence of MSC only slightly inhibited an unrelated MLC. Moreover, as reported by Tse et al, 13 we did not find any involvement of TGF-b or HGF in the inhibition of T-cell proliferation. A recent report suggested that IDO was expressed by MSC and might be responsible for the immunosuppression induced by them. 19 IDO catalyzes the conversion of tryptophan into kynurenine, and this tryptophan starvation in culture medium induces T-cell apoptosis. 18 As an example, IDO activity in mouse placenta has an essential role in preventing rejection of allogeneic fetuses. 20 Therefore, IDO sounds attractive as an explanation for the strong and broad inhibitory activity of MSC on the proliferation of T cells. Here, we have confirmed the intracellular expression of functional IDO by MSC and its activity in the supernatant of MSC/MLC cocultures. Therefore, IDO expression by MSC may be relevant in accounting for the immunomodulatory effect of MSC and could explain why previous studies were discordant. First, IDO seems to be expressed by MSC after IFNg exposure. This explains the absence of induction of apoptosis of nonstimulated T cells. Indeed, T cells could produce IFNg upon activation either in an allogeneic, mitogenic, or antigen-specific context. Furthermore, conditioned medium from resting MSC culture could remain nonsuppressive because it is not deprived of tryptophan unless MSC are cultured with IFNg. Second, an inhibitory experiment using conditioned medium from MLC could not work if tryptophan is incompletely catabolized. However, culture experiments using the transwell system to physically separate activated T cells from MSC could be useful to explore an inhibitory effect of MSC. Indeed, soluble factors, such as IFNg, released during T-cell activation could induce IDO expression by MSC and its activity, in spite of the presence of a separating membrane, leading to tryptophan deprivation of the culture medium, and then the induction of apoptosis of activated T cells.
We found that large amounts of MSC are necessary for inhibition of the proliferative response (MSC/PBMC ratio equal to 1/1.5). This explains why, because of their low frequency in the BM (0.001% of nucleated cells), their immunological properties are not observed after conventional BM transplantation. Therefore, therapeutic intervention will require in vitro MSC amplification. Interestingly, the immunosuppressive effect of MSC is observed from the first passage of cultures to the fourth, suggesting that this property is intrinsic to MSC, and maintained during culture and expansion. Furthermore, the inhibitory mechanism is radioresistant and g-irradiated MSC might be used in clinical trials.
The demonstration of the immunosuppressive effect of MSC in a full allogeneic assay suggests that an allogeneic source of MSC could be used in human treatment. The recent clinical report by Le Blanc et al, 7 performed with haploidentical MSC, suggests that control of the immunological response using ex vivo expanded MSC is feasible in humans, particularly in order to control the adverse effects of GVHD. Further studies should confirm the clinical benefit of the injection of MSC to control GVHD, and attempt to demonstrate in vivo that induction of alloreactive activated T-cell apoptosis by allogeneic MSC is involved in the clinical response.
